MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application

University of Ulm106 enrolled

Overview

The purpose of this study is to determine wether Mesna could prevent contrast-induced nephropathy

Contrast-induced nephropathy remains a common complication of radiographic precedures. Pretreatment with Mesna (Sodium 2-mercaptoethane sulfonate) in combination with sodium chloride is more protective than sodium chloride alone in animal models of acute renal failure. The aim of this study is therefore to determine laboratory and clinical benefit of MESNA, as an adjunct to saline hydration, in patients with known renal impairment receiving contrast media.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

106

Conditions

Chronic Renal Insufficiency Serum Creatinine Concentration Contrast Media Exposition

Interventions

sodium 2-mercaptoethane sulfonateDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * stable chronic renal insufficiency * serum creatinine concentration \> 1,5 mg/dl Exclusion Criteria: * Dialyzed patients * patients with acute renal failure * received iodinated contrast media within 7 days before study entry * known allery to Mesna, pregnancy, and administration of dopamine, mannitol or N-acetylcysteine

Locations (1)

Division of Nephrology, University of Ulm

Ulm, Germany

Outcomes

Primary Outcomes

Contrast-agent associated nephrotoxicity was defined as an increase in serum creatinine concentration >0.5 mg/dl (44 umol/l) of the baseline value 48 h after administration of the contrast media.

Secondary Outcomes

Need for dialysis after the administration of contrast media.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.